☆ 4.8 Article

Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC

Erica C. Nakajima et al.

Summary: The FDA has granted accelerated approval to sotorasib for the treatment of advanced non-small cell lung cancer with a KRAS G12C mutation. The drug has shown significant overall response rate and duration of response in clinical trials, with common adverse reactions including diarrhea and musculoskeletal pain.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

Marwan G. Fakih et al.

Summary: Sotorasib, a specific inhibitor of KRAS(G12C) protein, showed modest anti-tumour activity and manageable safety in heavily pretreated patients with colorectal cancer in a phase 2 trial. The overall response rate of 9.7% did not reach the benchmark, but sotorasib is being evaluated in combination with other therapeutics to enhance potential activity and address potential resistance mechanisms.

LANCET ONCOLOGY (2022)

Add to Collection

Review Oncology

ESMO 2021-highlights in colorectal cancer

Lukas Weiss

Summary: This review reflects on three abstracts on colorectal cancer presented at the 2021 ESMO Congress, covering new therapeutic targets, the potential role of selective internal radiotherapy, and the impact of the COVID-19 pandemic on CRC.

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications

Claudio Luchini et al.

Summary: Tumours with microsatellite instability (MSI)/defective DNA mismatch repair (dMMR) have low prevalence in pancreatic ductal adenocarcinoma (PDAC), associated with specific histological and molecular features. The clinical identification of MSI/dMMR PDAC requires specific tests and consideration of next-generation sequencing (NGS) for precision oncology.

GUT (2021)

Add to Collection

Article Oncology

FDAApproval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer

Shaily Arora et al.

Summary: FDA approved olaparib monotherapy and combination therapy with bevacizumab for the first-line treatment of advanced ovarian cancer with BRCA mutations and homologous recombination deficient-positive status. Both treatments demonstrated clinically meaningful improvements in progression-free survival and favorable benefit-risk profiles in clinical trials.

ONCOLOGIST (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Review Oncology

KRAS mutation in pancreatic cancer

Ji Luo

Summary: Pancreatic cancer is a difficult-to-treat cancer with low survival rates, commonly driven by oncogenic mutations in the KRAS gene. Therapeutic strategies targeting mutant KRAS show promise but face challenges in achieving clinical efficacy.

SEMINARS IN ONCOLOGY (2021)

Add to Collection

Review Oncology

Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology

Cedric Leroux et al.

Summary: The lack of early diagnosis, absence of suitable biomarkers, and resistance to available therapeutic options make pancreatic cancer one of the deadliest cancer types, necessitating the development of new therapeutic approaches. By considering the genetic and molecular profile of pancreatic tumors, potent and specific antitumor compounds can be developed to change this recalcitrant cancer type into a manageable one.

CANCERS (2021)

Add to Collection

Article Oncology

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials

Robert C. Doebele et al.

LANCET ONCOLOGY (2020)

Add to Collection

Review Oncology

The Frequency of Ras Mutations in Cancer

Ian A. Prior et al.

CANCER RESEARCH (2020)

Add to Collection

Article Oncology

EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

Vito Amodio et al.

CANCER DISCOVERY (2020)

Add to Collection

Article Medicine, General & Internal

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

David S. Hong et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Talia Golan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, Research & Experimental

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer

Andrew M. Waters et al.

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children

A. Drilon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Editorial Material Oncology

Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers

Vinay Prasad et al.

JAMA ONCOLOGY (2018)

Add to Collection

Article Multidisciplinary Sciences

Genomic analyses identify molecular subtypes of pancreatic cancer

Peter Bailey et al.

NATURE (2016)

Add to Collection

Article Multidisciplinary Sciences

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

Agnieszka K. Witkiewicz et al.

NATURE COMMUNICATIONS (2015)

Add to Collection

Article Oncology

Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial

Helmut Oettle et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection

Article Oncology

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer

A. H. Ko et al.

BRITISH JOURNAL OF CANCER (2013)

Add to Collection

Article Multidisciplinary Sciences

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Jonathan M. Ostrem et al.

NATURE (2013)

Add to Collection

Article Medicine, General & Internal

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Oncology

FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study

Alberto Zaniboni et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)

Add to Collection

Article Multidisciplinary Sciences

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

Andrew V. Biankin et al.

NATURE (2012)

Add to Collection

Article Medicine, General & Internal

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Article Oncology

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer

C. Yoo et al.

BRITISH JOURNAL OF CANCER (2009)

Add to Collection

Article Oncology

Phase 2 Trial of Oxaliplatin Plus Capecitabine (XELOX) as Second-line Therapy for Patients With Advanced Pancreatic Cancer

Henry Q. Xiong et al.

CANCER (2008)

Add to Collection

Article Multidisciplinary Sciences

Dynamic properties of the Ras switch I region and its importance for binding to effectors

M Spoerner et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.